Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Events
  5. Conferences

Conferences

Thumbnail
March 22, 2023

Second pivotal hit brings Claudin18.2 closer to approval

March 21, 2023

AACR 2023 – Moderna's immunotherapeutic splash

This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.

Article image
Vantage logo
March 20, 2023

AAD 2023 – Takeda outdoes Bristol’s Sotyktu

TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.

Article image
Vantage logo
March 20, 2023

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

But Humira remains the one to beat.

Article image
Vantage logo
March 16, 2023

World ADC 2023 – targeting the folate receptor rises from the ashes

Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.

Article image
Vantage logo
March 07, 2023

ACC 2023 – the market tries to take Medtronic’s pulse

Being first does not always mean a clear win.

Article image
Vantage logo
March 06, 2023

ACC 2023 – Merck’s oral cholesterol lowerer shows mid-stage promise

The oral PCSK9 project MK-0616 meets its targets in phase 2, which could be bad news for Novartis.

Article image
Vantage logo
March 06, 2023

ACC 2023 – Merck reaches for the stars

The Stellar trial of sotatercept lives up to its name, but the asset did not come cheap.

Article image
Vantage logo
March 06, 2023

ACC 2023 – Esperion investors don’t buy medics’ enthusiasm

Article image
Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

A 13% reduction in the risk of cardiovascular events is statistically significant but not spectacular.

Article image
Vantage logo
February 27, 2023

CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies

GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up